Intranasal IL-33 and Cholinergic Agonists in Mice

Mice were intranasally (i.n.) administered with recombinant mouse IL-33 (0.5 µg/dose, R&D, California, USA) in mice intraperitoneally (i.p.) administered with PNU-282987 (20 mg/kg, Abcam, California, USA) or GTS-21 (20 mg/kg, Abcam, California, USA) over three consecutive days (22 (link)). For Alternaria experiments, mice were i.n. administered with AA (100 µg/dose, Greer Labs, Lenoir, North Carolina, USA) in the presence or absence of PNU-282987 or GTS-21 on four consecutive days. Mice were sacrificed on the second day after the last challenge.

Free full text: Click here

Yuan F., Jiang L., Li Q., Sokulsky L., Wanyan Y., Wang L., Liu X., Zhou L., Tay H.L., Zhang G., Yang M, & Li F. (2021). A Selective α7 Nicotinic Acetylcholine Receptor Agonist, PNU-282987, Attenuates ILC2s Activation and Alternaria-Induced Airway Inflammation. Frontiers in Immunology, 11, 598165.

Publication 2020

recombinant mouse IL-33 PNU-282987 GTS-21

Alternaria Gts 21 Il 33 Mice Pnu 282987

Corresponding Organization : Hunter Medical Research Institute

Other organizations : Second Affiliated Hospital of Zhengzhou University, First Affiliated Hospital of Zhengzhou University

Top 5 similar protocols

Variable analysis

independent variables

Recombinant mouse IL-33 (0.5 µg/dose)
PNU-282987 (20 mg/kg)
GTS-21 (20 mg/kg)
Alternaria alternata (AA) (100 µg/dose)

dependent variables

Not explicitly mentioned

control variables

Not explicitly mentioned

controls

Positive control: Not mentioned
Negative control: Not mentioned

Annotations

Based on most similar protocols

Etiam vel ipsum. Morbi facilisis vestibulum nisl. Praesent cursus laoreet felis. Integer adipiscing pretium orci. Nulla facilisi. Quisque posuere bibendum purus. Nulla quam mauris, cursus eget, convallis ac, molestie non, enim. Aliquam congue. Quisque sagittis nonummy sapien. Proin molestie sem vitae urna. Maecenas lorem.

As authors may omit details in methods from publication, our AI will look for missing critical information across the 5 most similar protocols.

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!